![]() |
Volumn 4, Issue 1, 2009, Pages
|
No difference in between-country variability in use of newly approved orphan and non- orphan medicinal products - A pilot study
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABACAVIR PLUS LAMIVUDINE;
ADEFOVIR DIPIVOXIL;
APOMORPHINE;
BOSENTAN;
DESLORATADINE;
EFALIZUMAB;
EMTRICITABINE;
ETIRACETAM;
HYDROCHLOROTHIAZIDE PLUS TELMISARTAN;
IMATINIB;
KINZALKOMB;
NITISINONE;
ORPHAN DRUG;
OXYBATE SODIUM;
OXYBUTYNIN;
PREGABALIN;
UNCLASSIFIED DRUG;
WILZIN;
ZINC ACETATE;
ARTICLE;
AUSTRIA;
CONTROLLED STUDY;
DENMARK;
DRUG COST;
DRUG UTILIZATION;
FINLAND;
HUMAN;
NETHERLANDS;
PORTUGAL;
SWEDEN;
DRUG APPROVAL;
DRUG LEGISLATION;
DRUG MANUFACTURE;
ECONOMICS;
EUROPEAN UNION;
GOVERNMENT REGULATION;
HEALTH CARE DELIVERY;
LEGAL ASPECT;
PILOT STUDY;
RARE DISEASE;
STATISTICS;
AUSTRIA;
DENMARK;
DRUG APPROVAL;
DRUG UTILIZATION;
EUROPEAN UNION;
FINLAND;
GOVERNMENT REGULATION;
HEALTH SERVICES ACCESSIBILITY;
HUMANS;
LEGISLATION, DRUG;
NETHERLANDS;
ORPHAN DRUG PRODUCTION;
PILOT PROJECTS;
PORTUGAL;
RARE DISEASES;
SWEDEN;
|
EID: 75149126210
PISSN: None
EISSN: 17501172
Source Type: Journal
DOI: 10.1186/1750-1172-4-27 Document Type: Article |
Times cited : (16)
|
References (10)
|